Exelixis | EXEL - Net Income


Exelixis reported $218.1M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
Agios Pharmaceuticals USD -100.7M 1.59M Jun/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Amgen USD 3.86B 1.49B Sep/2026
AstraZeneca USD 3.12B 610M Sep/2026
Bayer EUR -672M 891M Sep/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Cytokinetics USD -190.07M 8.69M Sep/2026
Eisai JPY 11.69B 6.55B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Exelixis USD 218.1M 6.04M Sep/2026
Genmab DKK 303M 250M Jun/2026
Glaxosmithkline GBP 1.54B 194M Sep/2026
Incyte USD -784.8M 1.37B Sep/2026
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
MacroGenics USD 19.52M 56.29M Jun/2026
Merck USD 5.07B 6.4B Sep/2026
Moderna USD 162M 944M Sep/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Novartis USD 1.2B 2.06B Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR 343M 1.27B Jun/2026
Takeda JPY 192.43B 79.23B Sep/2026
Ultragenyx Pharmaceutical USD -118M 26M Sep/2026
Xencor USD -21.73M 107.19M Jun/2026